Further Information
Alternate Names/Synonyms:
XL184 malate; BMS907351 malate; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate
White to off white crystalline powder.
1140909-48-3
32160000
liquid
GHS07
Protect from light and moisture.
H302, H315, H319, H335
InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1
HFCFMRYTXDINDK-WNQIDUERSA-N
Chemical. CAS: 1140909-48-3. Formula: C32H30FN3O10. MW: 635.59. The s-malate salt form of Cabozantinib is very potent orally available inhibitor of multiple receptor tyrosine kinases (RTK), specifically MET and VEGFR2. It also inhibits KIT, FLT3, Tie-2, RET and AXL. Cabozantinib shows dose-dependent inhibition of tumor growth and tumor regression, associated with disruption of the tumor vasculature, angiogenesis and extensive tumor cell apoptosis.
MFCD20923480
C32H30FN3O10
635.59
Vial
P264, P280, P301+P312, P302+P352, P305+P351+P338, P332+P313, P337+P313
The s-malate salt form of Cabozantinib is very potent orally available inhibitor of multiple receptor tyrosine kinases (RTK), specifically MET and VEGFR2. It also inhibits KIT, FLT3, Tie-2, RET and AXL. Cabozantinib shows dose-dependent inhibition of tumor growth and tumor regression, associated with disruption of the tumor vasculature, angiogenesis and extensive tumor cell apoptosis.
>99% (HPLC)
O=C(C1(CC1)C(NC2=CC=C(F)C=C2)=O)NC(C=C3)=CC=C3OC4=CC=NC5=CC(OC)=C(OC)C=C54.O=C(O)C[C@H](O)C(O)=O
Soluble in DMSO.
Synthetic.
Non-hazardous
Biochemical Reagents
12352200
Stable for at least 2 years after receipt when stored at +4°C.